Audentes Therapeutics Inc (BOLD) Downgraded by Zacks Investment Research to Sell
Audentes Therapeutics Inc (NASDAQ:BOLD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
A number of other equities analysts have also recently issued reports on BOLD. Piper Jaffray Cos. started coverage on Audentes Therapeutics in a report on Monday, August 15th. They set an “overweight” rating and a $24.00 target price on the stock. Cowen and Company started coverage on Audentes Therapeutics in a report on Monday, August 15th. They set an “outperform” rating on the stock. Finally, Wedbush started coverage on Audentes Therapeutics in a report on Monday, August 15th. They set an “outperform” rating and a $20.00 price objective on the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/audentes-therapeutics-inc-bold-downgraded-by-zacks-investment-research-to-sell.html
Audentes Therapeutics (NASDAQ:BOLD) traded up 1.53% during trading on Wednesday, reaching $19.25. The company had a trading volume of 40,026 shares. Audentes Therapeutics has a 52-week low of $13.06 and a 52-week high of $20.42. The company has a 50 day moving average price of $15.91 and a 200 day moving average price of $15.51. The company’s market capitalization is $418.21 million.
In other news, Director Orbimed Advisors Llc bought 33,334 shares of the company’s stock in a transaction that occurred on Monday, July 25th. The shares were acquired at an average price of $15.00 per share, with a total value of $500,010.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Versant Ventures Iv, Llc bought 35,000 shares of the company’s stock in a transaction that occurred on Monday, July 25th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $525,000.00. The disclosure for this purchase can be found here.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.